<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01594866</url>
  </required_header>
  <id_info>
    <org_study_id>AYM-LEADERS</org_study_id>
    <nct_id>NCT01594866</nct_id>
  </id_info>
  <brief_title>Lexapro®'s Efficacy After Dose Escalation in Remission Study</brief_title>
  <acronym>LEADERS</acronym>
  <official_title>A Double-blinded 6-week Prospective Study to Evaluate the Remission Rate According to Dose of Escitalopram (Lexapro®) in Patients With Major Depressive Disorder: a Preliminary Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is the evaluation of remission rate between escitalopram 20 mg and
      30 mg in patients with major depressive disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, the investigators are going to examine the efficacy of escitalopram after dose
      escalation and evaluate remission rate. This study design is the double-blinded 6-week
      prospective study. It would be useful for clinicians because there were few study of
      high-dose antidepressant treatment in lack of remission in major depressive disorder
      patients. To control of bias, the investigators included patients with lack of remission
      after 4-week escitalopram treatment.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery-Åsberg Depression Rating Scale (MADRS)</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hamilton Depression Rating Scale-17 items (HAM-D)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Anxiety Rating Scale (HAM-A)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression-severity (CGI-S)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression-Improvement (CGI-I)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck's Depression Inventory(BDI)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WHO Quality Of Life scale Abbreviated Version(WHOQOL-BREF)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Useful Depression Outcome Scale (CUDOS)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short From-36 Health survey (SF-36 Health survey)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Escitalopram, 20mg, placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>escitalopram 20mg + placebo (same taste, appearance, texture of escitalopram 10mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Escitalopram 20mg, escitalopram 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escitalopram 20mg + Escitalopram 10mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>escitalopram</intervention_name>
    <description>escitalopram 20mg and 30mg p.o. daily, 6 weeks</description>
    <arm_group_label>Escitalopram, 20mg, placebo</arm_group_label>
    <arm_group_label>Escitalopram 20mg, escitalopram 10mg</arm_group_label>
    <other_name>Lexapro®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>escitalopram</intervention_name>
    <description>escitalopram 10mg p.o. for 1 week, and escitalopram 20mg p.o. for 3 weeks before randomized to placebo and experimental groups</description>
    <arm_group_label>Escitalopram, 20mg, placebo</arm_group_label>
    <arm_group_label>Escitalopram 20mg, escitalopram 10mg</arm_group_label>
    <other_name>Lexapro®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18 ~ 65

          -  Patient with major depressive disorder according to DSM-IV criteria

          -  Patient have signed on the informed consent, and well understood the objective and
             procedure of this study.

          -  MADRS total score ≥ 18

          -  Competent patient who is manage to answer the questionnaires.

          -  In case of female at child-bearing age, consent to use appropriate contraceptive
             methods(oral pill, contraceptive injection, intrauterine device, double barrier method
             and contraceptive patch) during entire duration of this study.

        Exclusion Criteria:

          -  In previous depressive episodes, no efficacy although more than one antidepressant
             treatment

          -  Allergy or hypersensitivity to escitalopram

          -  Diagnosed to schizophrenia or bipolar disorder or schizoaffective disorder (DSM-IV)

          -  MADRS 10 score ≥ 5, or patient who is supposed to be impossible to participate to this
             study due to clinical risk of suicide or aggressive behavior based on clinician's
             opinion

          -  Pregnant or breast-feeding female patient

          -  Significant biochemical or hematological abnormality or abnormal finding of
             urinalysis, based on clinician's opinion

          -  Significant severe medical condition

          -  Patients who take antipsychotics or mood stabilizer or other psychiatric drugs
             excluding benzodiazepines or beta blockers or hypnotics

          -  History of participating to other investigational drug trial within 1month prior to
             screening

          -  Investigator or employee at clinical trial center, personnel related to investigator
             or trial center on this or other study, or family of employee or investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong Min Ahn, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eun Young Kim, MD</last_name>
    <phone>82 2 2072 2457</phone>
    <email>npeunyoung@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yong Min Ahn, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2012</study_first_submitted>
  <study_first_submitted_qc>May 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2012</study_first_posted>
  <last_update_submitted>December 7, 2015</last_update_submitted>
  <last_update_submitted_qc>December 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Yong Min Ahn</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Major depressive disorder, remission, escitalopram</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

